{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:00:15Z","timestamp":1771455615817,"version":"3.50.1"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>A national Oral Cholera Vaccine (OCV) Euvichol-Plus\u00ae campaign was launched in Lebanon, in response to the first outbreak in three decades, recorded in October 2022. The OCV vaccination campaign was carried out between November 2022 and February 2023. This study aims to cover adverse events reports, received at the Lebanese National Pharmacovigilance Program\u2019s (LNPVP) passive surveillance system.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Case reports were extracted from the LNPVP\u2019s database. SPSS software was used to perform statistical analysis, with categorical variables compared using Pearson\u2019s <jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup> test. A descriptive analysis was performed based on age, gender, vaccine administered, and adverse event(s) associated with the administered vaccine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 115 Adverse Events Following Immunization (AEFIs) were reported, which corresponded to 46 case reports. The top three reported AEFIs were fever (39.13%), diarrhea (30.43%), and vomiting (30.43%). Reported cases were non-serious (82.6%). The highest proportion of Individual Case Safety Reports (ICSRs) received is attributed to females (56.5%), and the age category of 2 and 11\u2009years old (41.3%). Reporters\u2019 age range was 1\u201374 years old.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Monitoring AEFIs through the cholera outbreak\u2019s emergency campaign favors the safety profile of OCV.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2024.1480744","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T06:31:05Z","timestamp":1732084265000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Descriptive analysis of adverse events following immunization with oral cholera vaccine in Lebanon"],"prefix":"10.3389","volume":"12","author":[{"given":"Abeer","family":"Zeitoun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Reda El Sayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Hobeika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Karam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"ref1","year":"2024"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e680","DOI":"10.1016\/S2214-109X(18)30230-4","article-title":"Cholera epidemic in Yemen, 2016-18: an analysis of surveillance data","volume":"6","author":"Camacho","year":"2018","journal-title":"Lancet Glob Health"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"20572","DOI":"10.2807\/1560-7917.es2013.18.35.20572","article-title":"Cholera with severe renal failure in an Italian tourist returning from Cuba, July 2013","volume":"18","author":"Mascarello","year":"2013","journal-title":"Euro Surveill"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"30099","DOI":"10.2807\/1560-7917.ES.2016.21.1.30099","article-title":"Imported cholera with acute renal failure after a short business-trip to the Philippines, Germany, October 2015","volume":"21","author":"Slesak","year":"2016","journal-title":"Euro Surveill"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/14760584.2017.1291348","article-title":"PaxVax CVD 103-HgR single-dose live oral cholera vaccine","volume":"16","author":"Levine","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"ref6","year":"2022"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"722","DOI":"10.26719\/2011.17.8.722","article-title":"Two cases of Vibrio cholerae non-O1\/non-O139 septicaemia with favourable outcome in Lebanon","volume":"17","author":"Feghali","year":"2011","journal-title":"East Mediterr Health J"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/20477724.2021.1957192","article-title":"Factors influencing the occurrence of infectious disease outbreaks in Lebanon since the Syrian crisis","volume":"116","author":"Helou","year":"2022","journal-title":"Pathog Glob Health"},{"key":"ref9","volume-title":"Lebanon: Cholera outbreak","author":"Navqui","year":"2018"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/MS9.0000000000000293","article-title":"A minireview of cholera outbreak in Lebanon - a rising public health concern","volume":"85","author":"Berjaoui","year":"2023","journal-title":"Ann Med Surg"},{"key":"ref11","year":"2023"},{"key":"ref12","year":"2024"},{"key":"ref13","year":"2022"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40545-023-00528-1","article-title":"A 1-year analysis of adverse events following COVID-19 vaccination in Lebanon: a retrospective study","volume":"16","author":"Zeitoun","year":"2023","journal-title":"J Pharm Policy Pract"},{"key":"ref15","volume-title":"Adverse events following immunization for Covid-19 vaccines in Lebanon","author":"Karam","year":"2021"},{"key":"ref16","year":"2020"},{"key":"ref17","year":"2024"},{"key":"ref18","year":"2023"},{"key":"ref19","year":"2024"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"14573","DOI":"10.1002\/14651858.CD014573","article-title":"Oral killed cholera vaccines for preventing cholera","volume":"1","author":"Saif-Ur-Rahman","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"ref21","year":"2024"},{"key":"ref22","year":"2024"},{"key":"ref23","year":"2024"},{"key":"ref24","year":"2024"},{"key":"ref25","year":"2022"},{"key":"ref26","year":"2002"},{"key":"ref27","year":"2019"},{"key":"ref28","volume-title":"Casualty Assessment Software Dept of essential medicines and health products and the World Health Organization","year":"2019"},{"key":"ref29","year":"2024"},{"key":"ref30","year":"2024"},{"key":"ref31","year":""},{"key":"ref32","year":"2024"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3201\/eid2106.141797","article-title":"Oral cholera vaccine coverage, barriers to vaccination, and adverse events following vaccination, Haiti, 2013","volume":"21","author":"Tohme","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.vaccine.2021.01.017","article-title":"A reactive vaccination campaign with single dose oral cholera vaccine (OCV) during a cholera outbreak in Cameroon","volume":"39","author":"Amani","year":"2021","journal-title":"Vaccine"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s43441-022-00460-7","article-title":"Implementation of a pharmacovigilance system in a resources-limited country in the context of COVID-19: Lebanon's success story","volume":"57","author":"Abbas","year":"2023","journal-title":"Ther Innov Regul Sci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40545-022-00459-3","article-title":"Vaccination process evaluation at COVID-19 vaccination centers in Lebanon: a national study","volume":"15","author":"Zeitoun","year":"2022","journal-title":"J Pharm Policy Pract"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"A132","DOI":"10.1016\/j.vaccine.2019.08.086","article-title":"Global oral cholera vaccine use, 2013-2018","volume":"38","author":"Pezzoli","year":"2020","journal-title":"Vaccine"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"e038464","DOI":"10.1136\/bmjopen-2020-038464","article-title":"Use of surveys to evaluate an integrated oral cholera vaccine campaign in response to a cholera outbreak in Hoima district, Uganda","volume":"10","author":"Bwire","year":"2020","journal-title":"BMJ Open"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e0198592","DOI":"10.1371\/journal.pone.0198592","article-title":"Oral cholera vaccine coverage during a preventive door-to-door mass vaccination campaign in Nampula, Mozambique","volume":"13","author":"Sem\u00e1 Baltazar","year":"2018","journal-title":"PLoS One"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"211","DOI":"10.7774\/cevr.2021.10.3.211","article-title":"Adverse events following pediatric immunization in an Indian city","volume":"10","author":"Paramkusham","year":"2021","journal-title":"Clin Exp Vaccine Res"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12911-019-0818-8","article-title":"A statistical analysis of vaccine-adverse event data","volume":"19","author":"Ren","year":"2019","journal-title":"BMC Med Inform Decis Mak"},{"key":"ref42","year":"2023"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1586\/14760584.2015.1038249","article-title":"Adversomics: a new paradigm for vaccine safety and design","volume":"14","author":"Whitaker","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3390\/vaccines9111293","article-title":"Using population-based structures to actively monitor AEFIs during a mass immunization campaign-a case of measles-rubella and polio vaccines","volume":"9","author":"Kajungu","year":"2021","journal-title":"Vaccines"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how's and what's of vaccine reactogenicity","volume":"4","author":"Herv\u00e9","year":"2019","journal-title":"NPJ Vaccines"},{"key":"ref47","year":"2017"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1480744\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T06:31:08Z","timestamp":1732084268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1480744\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":47,"alternative-id":["10.3389\/fpubh.2024.1480744"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2024.1480744","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]},"article-number":"1480744"}}